← All trials
NCT04924868
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2021
- Primary completion
- Jul 1, 2025
- Completion date
- Jul 1, 2025
- First posted
- Jun 14, 2021
- Last posted
- Jun 14, 2021
- Enrollment
- 332
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University AlicanteLead sponsor
- University AlicanteReponsible party - principal investigator
- Universidad Carlos III MadridCollaborator
- University AlicanteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.